ReviewTherapeutic advances in hematology2019
Daratumumab in untreated newly diagnosed multiple myeloma.
Review in Therapeutic advances in hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review.Annals of hematology · 2021Pooled it
- Review
- The role of immunoglobins in atherosclerosis development; friends or foe?Molecular and cellular biochemistry · 2025Review
- Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?Biomedicines · 2025Review
- Daratumumab therapy in a pediatric case of C3 nephritic factor-positive proliferative glomerulonephritis with monoclonal IgG deposits.CEN case reports · 2024Article
- Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers.PharmacoEconomics - open · 2024Article
- Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel.Future oncology (London, England) · 2024Article
- Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell linesFrontiers in immunology · 2024Article
- Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe.Patient preference and adherence · 2024Article
- Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model.Cancer immunology, immunotherapy : CII · 2023Article
- Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.Frontiers in immunology · 2023Article
- Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review.Journal of family medicine and primary care · 2022Article
- Imaging for Plasma Cell Dyscrasias: What, When, and How?Frontiers in oncology · 2022Review
- B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.JACC. Basic to translational science · 2021Review
- Therapeutic Advances in Oncology.International journal of molecular sciences · 2021Review
- Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.Cancer immunology, immunotherapy : CII · 2021Article
- Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum.Communications biology · 2020Article
- EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.The oncologist · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies. Daratumumab, a fully human monoclonal antibody targeting CD38, has shown clinical efficacy in relapsed/refractory multiple myeloma both as monotherapy and in combination with other drugs, including novel agents. More recently, promising results have been reported in patients with untreated newly diagnosed multiple myeloma (NDMM). Clinical trials thus far have shown enhanced efficacy and tolerability of several daratumumab-based combinations in both transplant ineligible and eligible patients, without compromising transplant ability. However, benefit in high-risk subpopulations is still unclear. A subcutaneous formulation of daratumumab has been introduced to decrease the risk of infusion reactions, with preliminary results showing non-inferior efficacy. The antimyeloma activity of daratumumab is achieved through multiple mechanisms including direct, Fc-dependent, and immunomodulatory mechanisms. Enhanced efficacy of daratumumab in combination with immunomodulatory drugs and proteasome inhibitors is supported by preclinical data showing synergism. This review will focus on the role of daratumumab in untreated NDMM patients, highlighting the results of major clinical trials, and listing ongoing trials that are evaluating various daratumumab-based combinations in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.